Autogene cevumeran

Vaccine

Also known as RG6180, RO7198457

Phase 2Mechanism not established
Earlyevidence

Evidence outlook

Pancreatic Ductal Adenocarcinoma: mid-stage studies underway, no completed readout

In Pancreatic Ductal Adenocarcinoma, Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. Studies in other indications have read out; see the trials and Regulatory events below.

Development in Colorectal Cancer stopped (2026-08) after a negative readout. Development continues in another indication. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (5)
Pancreatic Ductal Adenocarcinoma
NCT05968326 · Genentech, Inc.
2023-10-18 – 2031-01-01 · Adenocarcinoma, Pancreatic Ductal
What this study did
Other / comorbidity
NCT06534983 · Hoffmann-La Roche
2024-12-09 – 2027-11-10 · Muscle-invasive Urothelial Carcinoma
What this study did
NCT04486378 · BioNTech SE
2021-03-08 – 2026-11 · Colorectal Cancer Stage II, Colorectal Cancer Stage III
What this study did
Phase 1 (2)
Other / comorbidity
NCT04161755 · Memorial Sloan Kettering Cancer Center
2019-12-13 – 2026-11-11 · Pancreatic Cancer
What this study did
NCT03289962 · Genentech, Inc.
2017-12-21 – 2025-07-01 · Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
What this study did

Competitive landscape

This drug's own stage for Pancreatic Ductal Adenocarcinoma: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Autogene Cevumeran: this drugPhase 2Vaccine—not yet gradedNo reviewed efficacy summary in this indication
Daraxonrasib (Rasonque)ApprovedSmall moleculepan-RAS, RAS (pan-RAS, RAS-mutant tumors)Partial signalNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
INCB161734Phase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
QuemliclustatPhase 3Small moleculeCD73 (NT5E)not yet gradedNo reviewed efficacy summary in this indication
SetidegrasibPhase 3Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
NavlimetostatPhase 2/3Small moleculePRMT5 (protein arginine methyltransferase 5), MTA-cooperative bindingnot yet gradedNo reviewed efficacy summary in this indication
ERAS-0015Phase 2Small moleculepan-RASnot yet gradedNo reviewed efficacy summary in this indication
GFH375Phase 2Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
Nuzefatide PevedotinPhase 2PeptideEphA2not yet gradedNo reviewed efficacy summary in this indication
ARV-806
Phase 1/2(overall)
Small moleculeKRAS G12Dnot yet gradedNo reviewed efficacy summary in this indication
VopimetostatPhase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
HSK41959
Phase 1(overall)
Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Autogene cevumeran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
November 2026 (1)
Phase 2Colorectal CancerActive not recruitingDiscontinued in this indication
Est. primary completion 2026-11 · NCT04486378 · CT.gov ↗
What to watch
2027 (1)
November 2027 (1)
Phase 2Muscle-invasive Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-11-10 · NCT06534983 · CT.gov ↗
What to watch
2031 (1)
January 2031 (1)
Phase 2Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2031-01-01 · NCT05968326 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 August 2026Topline resultPhase 2 BNT122-01 (NCT04486378) terminated for futility with overall survival numerical imbalance
BioNTech · Source ↗